Healio

Infliximab bests cyclophosphamide as first-line treatment of severe Behçet’s syndrome

Please provide your email address to receive an email when new articles are posted on . Week-22 remission rates were 81% among patients using infliximab and 56% in those on cyclophosphamide. Mild to ...
Pulse Today

Behçet’s disease – what it is and how to spot it

Dr Belinda Solomon describes how a case of Behçet’s disease was picked up in her clinic and explains how to recognise and ...
Medscape

British Societies Develop First 'Living' Behçet Guidelines

LIVERPOOL, ENGLAND — The British Society for Rheumatology (BSR) and the British Association of Dermatologists (BAD) have joined forces for the first time to develop the first British guidelines for ...
MarketWatch

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

The MarketWatch News Department was not involved in the creation of this content. -- Study results support advancing SGX945 in this difficult-to-treat orphan disease -- Results suggest potential ...
Seeking Alpha

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...
Morningstar

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

PRINCETON, N.J., Feb. 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
The New England Journal of Medicine

Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study

Methods We conducted a phase 2, multicenter, placebo-controlled study in which 111 patients with Behçet’s syndrome who had two or more oral ulcers were randomly assigned to receive 30 mg of apremilast ...
Nature

Behçet's Disease and Associated Conditions

Behçet's disease is a complex, multisystem inflammatory disorder characterised by recurrent mucocutaneous lesions, ocular involvement, and vascular, neurological, and gastrointestinal manifestations.
Nasdaq

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
sciencex

EULAR updates Behçet’s syndrome care, urging earlier monoclonal TNF inhibitors

The EULAR recommendations for the management of Behçet's syndrome were first published in 2008, and updated in 2018. Since that time, new evidence has become available, including trials of biologic ...
Seeking Alpha

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

PRINCETON, N.J., March 26, 2026 /PRNewswire/ --Soligenix, Inc. (SNGX) (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing ...